The French biopharma company Ipsen has announced the future acquisition of Albireo, a company specializing in drugs for rare diseases. A key drug Ipsen will gain from the deal is Bylvay, a drug used to treat rare pediatric liver diseases, including children with pruritus in progressive familiar intrahepatic cholestasis (PFIC).
According to Ipsen's CEO David Loew, “Our rare disease franchise is strengthened with Bylvay, which, in addition to being the first-approved treatment in PFIC, has two further indications being investigated in rare liver conditions that are underserved. Additionally, Bylvay and the clinical and preclinical novel bile acid transport inhibitors in Albireo's portfolio complement our own pipeline in liver disease”
To read more, click here.
(Source: PM Live, January 13th, 2022)
